Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
First preliminary efficacy data from the clinical trial with…
iOnctura announces expansion of roginolisib clinical trial program to NSCLC
• Phase II study in non-small-cell-lung-cancer (NSCLC) to be…
Curve Therapeutics strengthens Leadership Team with appointment of experienced biotech executive Simon Jones
Accomplished CFO and COO with proven track record in the…
A pill for infertility: Oxolife’s non-hormonal oral drug raises embryo implantation rate, pregnancy rates and live birth rate in women undergoing IVF and ICSI, data being presented at ESHRE shows
A pill for infertility: Oxolife’s non-hormonal oral drug raises…
Novo Holdings co-leads £90 million ($114 million) Series A financing for Myricx Bio to advance a novel payload class for antibody-drug conjugates
Funds will be used to build out Myricx Bio’s proprietary…
Mission Therapeutics awarded $5.2m from The Michael J. Fox Foundation and Parkinson’s UK to advance potential disease-modifying treatment MTX325
Investment will support investigation of Mission’s small…
Novo Holdings invests in MATR Foods’ expansion within plant-based fungi food
COPENHAGEN, DENMARK – Today, Novo Holdings announced an initial…
Tom Tacon appointed Business Unit Director of Bionical Virtual Engagement
Willington, UK, June 27, 2024 – Bionical Solutions, a leading…
Resolution Therapeutics Receives MHRA Approval to Commence Phase I/II EMERALD Study for Lead Candidate RTX001
EMERALD Study will investigate safety and efficacy of engineered…
Fostrox + Lenvima® holds promise of greatly improved outcomes for advanced liver cancer patients, reveals new data from Medivir at ESMO GI
New results from Medivir’s Phase 1b / 2a open label trial…
Novo Holdings and DLG Group join forces to advance sustainable crop production
Novo Holdings and DLG Group today announced a strategic partnership…
Novo Holdings announces investment in AgNext Technologies, an agricultural and food technology company developing AI-based solutions for more sustainable agriculture
Copenhagen and Singapore, 25 June 2024 - Novo Holdings today…
AMSilk to showcase its biofabricated yarns at Première Vision Paris
Neuried, Germany, 25 June 2024: AMSilk GmbH (“AMSilk”), a…
4SC AG: AGM highlights – Positive progress in 2023/2024 leaves company well positioned for resminostat commercialisation
Planegg-Martinsried, Germany, 20 June 2024 – 4SC AG (4SC,…
iOnctura announces EUR80 million Series B financing to progress pipeline through Phase II trials
• Led by new investor Syncona, with participation from the…
Independent Cradle-to-Gate life cycle assessment shows AMSilk’s fibers have a significantly lower environmental footprint compared to silk
Neuried, Germany, 20 June 2024: AMSilk GmbH (“AMSilk”), a…
Gareth Williams appointed CEO of Bionical Health
Willington, UK, June 19, 2024 – Bionical Solutions, a leading…
Calliditas provides setanaxib patent update
Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm:…
AMSilk attends Pitti Filati for the first time to showcase biofabricated premium yarns
Neuried, Germany, 18 June 2024: AMSilk GmbH (“AMSilk”), a…
We’d love to hear from you.
For more information about Optimum Strategic Communications, please get in touch.
We are specialists with an indepth understanding of how to communicate complex science to investors and corporate stakeholders. We help companies on their journey as they grow and have been trusted by hundreds of clients from around the world, both public and private, large and small.
Locations
- London
- Amsterdam
- Stockholm
- Zurich
- New York